58 Results for "

Compound 31

" in MedChemExpress (MCE) Product Catalog:
Products (58)

58 Results for "Compound 31" in MCE Product Catalog:

Cat. No.: HY-168051
Research Areas:  

Neurological Disease Cancer

TLX agonist 2 (compound 31) is a TLX agonist (EC50=0.1 μM; Kd=0.16 μM). TLX agonist 2 promotes TLX transcriptional activity and enhances the expression of TLX target genes by binding to TLX. TLX agonist 2 can be used in the study of neurodegenerative diseases .
loading...
    loading...
Cat. No.: HY-161401
PAR4 antagonist 2 (Compound 31) is a protease activated receptor 4 (PAR4) antagonist, with IC50 values of 95 nM and 367 nM for human PAR4 and mouse PAR4. PAR4 antagonist 2 is active against PAR4 activation by the native protease thrombin cleavage but not the synthetic PAR4 agonist peptide AYPGKF .
loading...
    loading...
Cat. No.: HY-179118
Target:  

Parasite

Research Areas:  

Infection

Antimalarial agent 53 (compound 31) is an antimalarial agent. Antimalarial agent 53 blocks protein synthesis by inhibiting the cytoplasmic ribosomes of malaria parasites, exhibiting potent antimalarial activity (IC50 = 3.9 nM) and good selectivity. Antimalarial agent 53 has no cross resistance and good safety. Antimalarial agent 53 can be used for research on malaria .
loading...
    loading...
Cat. No.: HY-173509
CAS No.: 2023027-81-6
ATX inhibitor 27 (Compound 31) is an ATX inhibitor. The IC50 values of ATX inhibitor 27 against human autotaxin (hATX) and lysophosphatidylcholine (LPC) are 13 nM and 23 nM, respectively. ATX inhibitor 27 reduces LPA levels in vivo by inhibiting ATX enzyme. ATX inhibitor 27 can be used in the study of ATX-LPA-related diseases such as inflammation, neurodegenerative diseases and cancer .
loading...
    loading...
Cat. No.: HY-156286
Target:  

Ferroptosis

Research Areas:  

Cancer

GPX4-IN-7 (Compound 31), indirubin derivative, is a ferroptosis inducer for colon cancer. GPX4-IN-7 has strong antitumor activity against HCT-116 cells with an IC50 value of 0.49 μM. GPX4-IN-7 can promote the degradation of GPX4, causing the accumulation of lipid ROS to induce ferroptosis .
loading...
    loading...
Cat. No.: HY-169925
CAS No.: 1391107-57-5
Target:  

Bcl-2 Family

Research Areas:  

Cancer

BM-962 (Compound 31) is a potent small-molecule inhibitor of Bcl-2 with an IC50 value of 4 nM (Ki=0.8 nM) and Bcl-xL with an IC50 value of 3.9 nM (Ki <1 nM). BM-962 inhibits the cell growth in H1417 and H146 cell lines with IC50 values of 9 and 13 nM, respectively. BM-962 is promising for research of cancers .
loading...
    loading...
Cat. No.: HY-174348
CAS No.: 3051852-76-4
Research Areas:  

Inflammation/Immunology

BRD4-IN-10 (Compound 31) is a selective BRD4 inhibitor with an IC50 of 13.5 nM. BRD4-IN-10 can exert anti-inflammatory and anti-fibrotic effects. BRD4-IN-10 also has good metabolic stability, pharmacokinetic properties and safety. BRD4-IN-10 can be used in the research of renal fibrosis diseases .
loading...
    loading...
Cat. No.: HY-N12521
CAS No.: 145163-97-9
(3β,24S)-3-Hydroxystigmast-5-en-7-one (Compound 31) is a compound that can be isolated from Lindera akoensis . (3β,24S)-3-Hydroxystigmast-5-en-7-one has anti-inflammatory activity .
loading...
    loading...
Cat. No.: HY-172252
Target:  

PD-1/PD-L1 RAD51

Research Areas:  

Cancer

CSN5-IN-2 (Compound 31) is a CSN5 inhibitor with an IC50 of 0.36 μM. CSN5-IN-2 can increase the level of Cullin 1 neddylation, and downregulate the expression of RAD51 and PD-L1 in cancer cells. CSN5-IN-2 has anti-tumor activity, and its effect is better when combined with Talazoparib (HY-16106) .
loading...
    loading...
Cat. No.: HY-170497
Target:  

EGFR

Research Areas:  

Cancer

EGFR-IN-140 (Compound 31) is the inhibitor for EGFR, that inhibits EGFR wildtype and EGFR L858R/T790M/C797S mutant with Ki of 0.95 nM and 2.1 nM, and inhibits EGFR del19/T790M/C797S in Ba/F3 with an IC50 of 56.9 nM. EGFR-IN-140 exhibits antitumor efficacy in mouse model .
loading...
    loading...
Cat. No.: HY-16641
CAS No.: 1315490-71-1
Target:  

JAK

Research Areas:  

Cancer

JAK1-IN-17 (Compound 31) is a highly selective inhibitor of JAK1 with a Ki of 1.9 nM. JAK1-IN-17 exhibits a low whole blood shift, which allows maintaining good whole blood potency. JAK1-IN-17 is also a nitrile-containing analogue with consistent, yet weak reversible inhibition of CYP3A4 using a midazolam probe (IC50 = 7.9 μM). JAK1-IN-17 can be studied in cancer research .
loading...
    loading...
Cat. No.: HY-158688
CAS No.: 3048633-11-7
Target:  

PI3K

Research Areas:  

Inflammation/Immunology

PI3Kδ-IN-21 (Compound 31) is a selective inhibitor for phosphoinositide 3-kinases δ (PI3Kδ), with an IC50 of 13.6 nM. PI3Kδ-IN-21 inhibits proliferation and differentation of T cells through PI3K/AKT/mTOR signaling pathway. PI3Kδ-IN-21 exhibits good pharmacokinetic characters in rat model, and attenuates the experimental autoimmune encephalomyelitis in myelin oligodendrocyte glycoprotein (MOG)-induced EAE model .
loading...
    loading...
Cat. No.: HY-159966
CAS No.: 3059615-90-3
Top/HDAC-IN-3 (Compound 31) is an orally active dual inhibitor of Topoisomerase and HDAC. Top/HDAC-IN-3 increases reactive oxygen species (ROS) levels, leading to DNA damage, thereby inhibiting cancer cell colony formation and migration, inducing cancer cell Apoptosis, and causing cell cycle arrest. In the NSCLC model, Top/HDAC-IN-3 exhibited significant antitumor effects, with a tumor growth inhibition (TGI) of 77.5% at 100 mg/kg, surpassing the efficacy of the HDAC inhibitor SAHA (HY-10221) and the combination of SAHA (HY-10221) with the topoisomerase inhibitor Irinotecan (HY-16562) .
loading...
    loading...
Cat. No.: HY-172889
CAS No.: 3085191-45-0
Target:  

PI3K HDAC Apoptosis mTOR Akt

Research Areas:  

Cancer

PI3K/HDAC-IN-4 (Compound 31f) is a PI3K/HDAC dual inhibitor (IC50: 0.2μM). PI3K/HDAC-IN-4 shows high selectivity for HDAC1-3 (IC50 values of 75.5 nM, 70.9 nM, and 1.9 nM, respectively). PI3K/HDAC-IN-4 is a potent PIK3 inhibitor with IC50 values of 2.5 nM, 80.5 nM, 10.0 nM, and 57.2 nM for PI3Kα, β, δ, and γ, respectively. PI3K/HDAC-IN-4 significantly induces tumor cell apoptosis by simultaneously inhibiting the PI3K/AKT/mTOR signaling pathway and HDAC1-3. PI3K/HDAC-IN-4 exhibits potent antiproliferative activity in a variety of tumor cell lines (e.g., MV4-11, Jeko-1, HL60, and MCF-7, with IC50 values of 0.2, 0.9, 0.8, and 1.5 μM, respectively). PI3K/HDAC-IN-4 can be used in the study of lymphoma and leukemia .
loading...
    loading...
Cat. No.: HY-W342853
CAS No.: 58954-23-7
Target:  

Endogenous Metabolite

Research Areas:  

Inflammation/Immunology Cancer

HPSE-IN-1 (Compound 31) is a heparanase inhibitor with an IC50 of 970 µM. HPSE-IN-1 can be used in the research of inflammatory diseases and cancer .
loading...
    loading...
Cat. No.: HY-158792
CAS No.: 1899930-93-8
Target:  

Others

Research Areas:  

Others

GK241 (compound 31a-c) is a 2-oxoamide-based compound that has inhibitory activity against human and mouse group IIA secretory phospholipase A2 (GIIA sPLA2) (IC50 of 143 nM and 68 nM, respectively), and its inhibitory mechanism was studied by molecular dynamics simulation.
loading...
    loading...
Cat. No.: HY-148227
CAS No.: 2226490-67-9
Research Areas:  

Cancer

Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB-MMAE (Compound 31) is a Drug-Linker Conjugates for ADC. Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB-MMAE is composed of MMAE (HY-15162) and Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB carbonic acid (HY-171663) .
loading...
    loading...
Cat. No.: HY-186021
CAS No.: 2918762-17-9
Target:  

PROTACs YAP

Research Areas:  

Cancer

PROTAC TEAD degrader-2 (Compound 31) is an efficient TEAD1 PROTAC degrader with a DC50 of 0.6 nM. PROTAC TEAD degrader-2 inhibits the YAP/TAZ-TEAD interaction, with a IC50 of 1.8 nM. PROTAC TEAD degrader-2 exhibits significant selective inhibitory activity against YAP-dependent cancer cells and effectively suppresses the transcriptional activity mediated by YAP. PROTAC TEAD degrader-2 can be used for research on mesothelioma and glioma .
loading...
    loading...